BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

708 related articles for article (PubMed ID: 35795662)

  • 1. Immunity and Extracellular Matrix Characteristics of Breast Cancer Subtypes Based on Identification by T Helper Cells Profiling.
    Zhou Y; Tian Q; Gao H; Zhu L; Zhang Y; Zhang C; Yang J; Wang B
    Front Immunol; 2022; 13():859581. PubMed ID: 35795662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The regulatory roles of T helper cells in distinct extracellular matrix characterization in breast cancer.
    Tian Q; Gao H; Ma Y; Zhu L; Zhou Y; Shen Y; Wang B
    Front Immunol; 2022; 13():871742. PubMed ID: 36159822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3D Collagen Fiber Concentration Regulates Treg Cell Infiltration in Triple Negative Breast Cancer.
    Gao H; Tian Q; Zhou Y; Zhu L; Lu Y; Ma Y; Feng J; Jiang Y; Wang B
    Front Immunol; 2022; 13():904418. PubMed ID: 35774776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a five genes prognosis signature for triple-negative breast cancer using multi-omics methods and bioinformatics analysis.
    Ma J; Chen C; Liu S; Ji J; Wu D; Huang P; Wei D; Fan Z; Ren L
    Cancer Gene Ther; 2022 Nov; 29(11):1578-1589. PubMed ID: 35474355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel model associated with tumor microenvironment on predicting prognosis and immunotherapy in triple negative breast cancer.
    Zhang J; Zhang M; Tian Q; Yang J
    Clin Exp Med; 2023 Nov; 23(7):3867-3881. PubMed ID: 37219794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of m6A modification patterns and development of m6A-hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer.
    Shen X; Zhong J; He J; Han J; Chen N
    Front Immunol; 2022; 13():978092. PubMed ID: 36105819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KEGG-expressed genes and pathways in triple negative breast cancer: Protocol for a systematic review and data mining.
    Chen J; Liu C; Cen J; Liang T; Xue J; Zeng H; Zhang Z; Xu G; Yu C; Lu Z; Wang Z; Jiang J; Zhan X; Zeng J
    Medicine (Baltimore); 2020 May; 99(18):e19986. PubMed ID: 32358373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of key genes as potential biomarkers for triple‑negative breast cancer using integrating genomics analysis.
    Zhong G; Lou W; Shen Q; Yu K; Zheng Y
    Mol Med Rep; 2020 Feb; 21(2):557-566. PubMed ID: 31974598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Landscape of toll-like receptors expression in tumor microenvironment of triple negative breast cancer (TNBC): Distinct roles of TLR4 and TLR8.
    Roychowdhury A; Jondhale M; Saldanha E; Ghosh D; Kumar Panda C; Chandrani P; Mukherjee N
    Gene; 2021 Aug; 792():145728. PubMed ID: 34022297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel fatty-acid metabolism-based classification for triple negative breast cancer.
    Yang X; Tang W; He Y; An H; Wang J
    Aging (Albany NY); 2023 Feb; 15(4):1177-1198. PubMed ID: 36880837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer.
    Qiu P; Guo Q; Yao Q; Chen J; Lin J
    Front Immunol; 2021; 12():736030. PubMed ID: 34659224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of comprehensive typing based on m6A and gene cluster in TNBC.
    Wu H; Feng J; Wu J; Zhong W; Zouxu X; Huang W; Huang X; Yi J; Wang X
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4367-4380. PubMed ID: 36109402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma
    Lou X; Zhao K; Xu J; Shuai L; Niu H; Cao Z; Wang J; Zhang Y
    Front Immunol; 2022; 13():950213. PubMed ID: 36072582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Research and experimental verification on the mechanisms of cellular senescence in triple-negative breast cancer.
    Cao T; Huang M; Huang X; Tang T
    PeerJ; 2024; 12():e16935. PubMed ID: 38435998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Key Genes and Pathways in Triple-Negative Breast Cancer by Integrated Bioinformatics Analysis.
    Dong P; Yu B; Pan L; Tian X; Liu F
    Biomed Res Int; 2018; 2018():2760918. PubMed ID: 30175120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
    Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
    Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ARNTL2 is a Prognostic Biomarker and Correlates with Immune Cell Infiltration in Triple-Negative Breast Cancer.
    Wang X; Li Y; Fu J; Zhou K; Wang T
    Pharmgenomics Pers Med; 2021; 14():1425-1440. PubMed ID: 34785930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A senescence-based prognostic gene signature for colorectal cancer and identification of the role of SPP1-positive macrophages in tumor senescence.
    Yu S; Chen M; Xu L; Mao E; Sun S
    Front Immunol; 2023; 14():1175490. PubMed ID: 37090726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel tumor purity and immune infiltration-related model for predicting distant metastasis-free survival in prostate cancer.
    Su Q; Zhu Y; He B; Dai B; Mu W; Tian J
    Eur J Med Res; 2023 Nov; 28(1):545. PubMed ID: 38017548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of new subtypes and potential genetic signatures in triple-negative breast cancer using weighted gene co-expression network analysis.
    Huang J; Liao LY; Jiang WJ; Li YH; Lu BM; Wen ZP; Li FJ; Fang DL; Lu GM
    Eur Rev Med Pharmacol Sci; 2024 Jan; 28(2):603-614. PubMed ID: 38305604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.